TY - JOUR
AU - Passley Hargrove-Grimes
AU - Lucie A. Low
AU - Danilo A. Tagle
AB - Microphysiological systems (MPS) or tissue chips/organs-on-chips are novel <i>in vitro</i> models that emulate human physiology at the most basic functional level. In this review, we discuss various hurdles to widespread adoption of MPS technology focusing on issues from multiple stakeholder sectors, e.g., academic MPS developers, commercial suppliers of platforms, the pharmaceutical and biotechnology industries, and regulatory organizations. Broad adoption of MPS technology has thus far been limited by a gap in translation between platform developers, end-users, regulatory agencies, and the pharmaceutical industry. In this brief review, we offer a perspective on the existing barriers and how end-users may help surmount these obstacles to achieve broader adoption of MPS technology.
BT - Cells Tissues Organs
DA - 2022
DO - 10.1159/000517422
IS - 3
LA - english
N2 - Microphysiological systems (MPS) or tissue chips/organs-on-chips are novel <i>in vitro</i> models that emulate human physiology at the most basic functional level. In this review, we discuss various hurdles to widespread adoption of MPS technology focusing on issues from multiple stakeholder sectors, e.g., academic MPS developers, commercial suppliers of platforms, the pharmaceutical and biotechnology industries, and regulatory organizations. Broad adoption of MPS technology has thus far been limited by a gap in translation between platform developers, end-users, regulatory agencies, and the pharmaceutical industry. In this brief review, we offer a perspective on the existing barriers and how end-users may help surmount these obstacles to achieve broader adoption of MPS technology.
PY - 2022
SP - 269
EP - 281
ST - Microphysiological Systems
T2 - Cells Tissues Organs
TI - Microphysiological Systems: Stakeholder Challenges to Adoption in Drug Development
UR - https://www.karger.com/Article/FullText/517422
VL - 211
Y2 - 2022-12-01
SN - 1422-6405, 1422-6421
ER -